This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Positive interim results from Moderna’s Phase I/II trial of mRNA-1083 , an investigational vaccine designed to immunise against both influenza and COVID-19, have been released. There are several benefits of the combination vaccine as a preventative measure against these respiratory conditions, according to the pharmaceuticalcompany.
As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.
Published June 16, 2025 By Kelly Bilodeau post share post print email license Stock via Getty Images Listen to the article 9 min This audio is auto-generated. By Amy Baxter • June 16, 2025 Keep up with the story. By Amy Baxter • June 16, 2025 Latest in Patient Will pharma finally score a policy win for 340B?
In an interview with Pharmacy Times® , Gabe Hinojosa, PharmD, BCOP, clinical pharmacy specialist oncology/hematology at UT Southwestern, discussed the evolving treatment landscape for multiple myeloma (MM) and presented data from the 2025 American Society of Clinical Oncology Annual Meeting (ASCO).
Soefje, PharmD, MBA, BCOP, during the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon. In 2022, based upon a complaint filed by a pharmaceuticalcompany, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. This went into effect in January 2022.”
Pharmaceuticalcompanies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. ClevelandClinic.org (accessed June 20, 2025). Press Release, March 6, 2025. Press Release, March 2, 2022. Punctal Plugs.
How will RFK Jr’s American dream for vaccines play out? July 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Zentiva will manage commercial activities primarily within Europe and CIS markets, excluding the US and Canada. Credit: Zentiva Group, a.s. Sign up for our daily news round-up!
How will RFK Jr’s American dream for vaccines play out? Uruguay’s new left-wing coalition government took office in March 2025, under President Yamandu Orsi. The new agency will absorb the existing MSP’s pharmaceutical regulatory functions, including drug licensing, quality control and price regulation.
How will RFK Jr’s American dream for vaccines play out? July 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Targeted protein degradation (TPD) represents a transformative approach within the field of therapeutic intervention, specifically for diseases where traditional small-molecule inhibitors have failed.
The platform provides a means of technical exchange on high-quality, ready-to-fill primary packaging between pharmaceuticalcompanies, contract manufacturers, and contract development and manufacturing organizations. June 30, 2025. Pharmapack Europe 2025: Packaging Trends. Sterile capsules for injection. . References 1.
More recently, the rapid development of Moderna’s COVID-19 vaccine, which used many of the principles of synthetic biology, is yet more proof that this is an area on the cusp of the pharmaceutical R&D mainstream. About the interviewee.
If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. And those volumes will only increase.
Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. As technology has evolved, biotech and pharmaceuticalcompanies have increasingly leaned on AI to support drug development – including to make sense of the vast amounts of healthcare data available to them.
Propelled by constant innovatory winds, the Cell and Gene therapy market is anticipated to grow by 20 percent year-over-year through 2025. The company received its first approval from the Japanese government in 2019 to treat critical limb ischemia. With a total revenue of $52B, Merck & Co.
There have been several biosimilars approved, including Wezlana , Selarsdi, and Pyzchiva, but they are not expected to be available until early 2025. It is made by the pharmaceuticalcompany Amgen, Inc. But Stelara is a biologic product , meaning it will have what’s called a biosimilar instead of a generic version.
During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry. While production volumes have now fallen, future vaccine demand is hard to predict, as booster shots could be needed at any point to control emerging variants.
Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. As a result, some pharmaceuticalcompanies are turning to third parties.
4,5 DREAMM-7 In DREAMM-7, patients with RRMM who had received at least 1 prior line of therapy were randomized 1:1 to receive belantamab mafodotin plus bortezomib (Velcade; Millennium/Takeda and Janssen PharmaceuticalCompanies) and dexamethasone (BVd) compared with daratumumab (Darzalex; Johnson & Johnson), bortezomib, and dexamethasone (DVd).
Image Credit: Adobe Stock Images/Artur.com Key Takeaways Sanofi is shipping Beyfortus early to ensure strong supply for the 2025–2026 RSV season and avoid past shortages. and outperformed maternal vaccines in public health programs. Sanofi and AstraZeneca have tripled production capacity to meet growing demand.
The development of COVID-19 vaccines required levels of cooperation and pioneering science comparable to the Apollo space programme. Within 12 months of the outbreak, vaccines were being deployed to prevent severe infections, hospitalisation, and death. billion people have been fully vaccinated. And there are many.
IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.
This law enables Medicare to negotiate directly with pharmaceuticalcompanies, which should ultimately result in lower prescription drug costs for consumers. Under the new law, there will also be a Part D out-of-pocket price cap of $2,000 starting in 2025.
Made by the pharmaceuticalcompany Janssen Biotech, Inc., While you are on Stelara, you should not receive live vaccines , including MMR, varicella, rotavirus, nasal flu vaccine, or the Bacillus Calmette–Guérin (BCG) vaccine , which is used to prevent TB in high-risk people in some countries.
The law will allow Medicare to negotiate directly with pharmaceuticalcompanies to improve access to affordable prescription drug costs. How the prescription drug law affects Jardiance In January 2023, a new prescription drug law went into effect as part of the Inflation Reduction Act.
Scientific experts are concerned about what role vaccines will play in US public health strategy under the Trump administration. Robert Barrie June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook RFK Jr has embarked on a mission to reset vaccine regulation and evidence generation in the US.
3 Additionally, tariffs could increase lead times for manufacturing, as companies navigate customs barriers and seek alternative suppliers. For complex treatments such as biologics and vaccines, which require highly specialised production facilities, shifting supply chains is neither simple nor immediate. Available from: [link] 2.
Robert Barrie and Ross Law June 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The removal ACIP members marks the most significant upheaval to the current vaccine landscape under Trump’s administration. lev radin via Shutterstock. lev radin via Shutterstock.
How will RFK Jr’s American dream for vaccines play out? Impacts on pharma Pharmaceuticals and APIs are currently exempt from the 10% baseline tariffs and reciprocal tax rates for specific trade partners introduced by the Trump Administration in April 2025. Login Registration is disabled.
Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80 each month. “I Mochi Health is even the subject of a lawsuit initiated by Eli Lilly.
Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Drugmakers have poured billions of dollars into pharma manufacturing facilities across the US as they adapt to macroeconomic pressures. Novartis, Eli Lilly, and Genentech have also made US investment announcements in the wake of Trump’s reforms.
How will RFK Jr’s American dream for vaccines play out? Abigail Beaney July 9, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US President Trump had previously suggested 25% tariffs on the pharmaceutical sector. Image credit: Andrew Harnik via Getty Images. Login Registration is disabled.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content